Incidence Trends and Burden of Human Papillomavirus-Associated Cancers Among Women in the United States, 2001-2017

JNCI Journal of the National Cancer Institute, Год журнала: 2020, Номер 113(6), С. 792 - 796

Опубликована: Авг. 19, 2020

Human papillomavirus (HPV)-associated anal and oropharyngeal cancer incidence has increased in recent years among US women. However, trends burden (annual number of cases) noncervical HPV-associated cancers relative to cervical remain unclear. Using the 2001-2017 statistics dataset, we evaluated contemporary women by anatomic site, race or ethnicity, age. Overall, plateaued White but continued decline Black Hispanic Anal surpassed aged 65-74 age (8.6 8.2 per 100 000 2015) 75 older (6.2 6.0 2014). The (n = 11 871) 527) 2013. Development efficacious screening strategies for improvement prevention are needed combat

Язык: Английский

---

Sensitivity and Specificity of Human Papillomavirus (HPV) 16 Early Antigen Serology for HPV-Driven Oropharyngeal Cancer: A Systematic Literature Review and Meta-Analysis

Cancers, Год журнала: 2021, Номер 13(12), С. 3010 - 3010

Опубликована: Июнь 16, 2021

Antibodies against HPV16 early proteins have been shown to be promising biomarkers for the identification of HPV-driven oropharyngeal cancer (HPV-OPC) among OPC cases in multiple studies. A systematic literature search was performed identify original research articles comparing HPV antigen serology with established reference methods determine molecular tumor status. Random-effects models were used calculate summary estimates sensitivity and specificity E2, E6 E7 HPV-OPC. Subgroup analyses explore heterogeneity across studies describe variables associated test performance. We identified n = 23 meeting all eligibility criteria included these meta-analysis. showed best performance pooled 83.1% (95% confidence interval (CI) 72.5-90.2%) 94.6% CI 89.0-97.4%), respectively, while E2 serological assays highly specific (E2: 92.5% 79.1-97.6%); E7: 88.5% 77.9-94.4%)) but moderately sensitive 67.8% 58.9-75.6%); 67.0% 63.2-70.6%)). revealed increased bacterially (89.9% 84.5-93.6%)) vs. vitro expressed (55.3% 41.0-68.7%)), both high (95.2% 93.0-96.7%) 91.1% 46.6-99.2%), respectively). Pooled significantly lower utilizing DNA PCR as only method compared those using a combination any two (HPV DNA, RNA, situ hybridization (ISH), p16 immunohistochemistry (IHC)), or histopathological (ISH IHC) stand-alone marker. In conclusion, seropositivity is biomarker However, its differs between depends on methods.

Язык: Английский

---

Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: A modeling study

The Lancet Regional Health - Americas, Год журнала: 2021, Номер 8, С. 100143 - 100143

Опубликована: Дек. 15, 2021

Oropharyngeal cancer (OPC) incidence is rising rapidly among men in the United States of America (USA). We aimed to project impact maintaining current HPV vaccination uptake and achieving 80% national (Healthy People) goal on OPC burden. developed an open-cohort micro-simulation model natural history contemporary future birth cohorts men, accounting for sexual behaviors, population growth, aging, herd immunity. used data from nationally representative databases, registries all 50 states, large clinical trials, literature. evaluated status quo scenario (the remained stable) alternative scenarios improvements rates adolescents (aged 9-17 years) young adults 18-26 by 2025 achieve maintain goal. The primary outcome was burden 2009 2100. also assessed disruption vaccine during COVID-19 pandemic. projected rise until mid-2030s, reaching age-standardized rate 9·8 (95% uncertainty interval [UI] 9·5-10·1) per 100 000 with peak annual 23 850 (UI, 200-24 500) cases. Under scenario, could prevent 124 117 000-131 000) 2060, 400 384 000-416 2080, 792 763 000-821 2100 cases men. Achievement maintenance coverage adolescent girls only, boys, plus additional number 95 000-105 000), 118 113 000-123 142 136 000-148 male Delayed recovery pandemic lead 600 580-620) 6200 5940-6460) 2100, conditional decline extent potential delay rebounding. USA. Nationwide efforts should be a public health priority. Rapid declined crucial excess National Cancer Institute Minority Health Disparities

Язык: Английский

---

Salivary High-Risk Human Papillomavirus (HPV) DNA as a Biomarker for HPV-Driven Head and Neck Cancers

Journal of Molecular Diagnostics, Год журнала: 2021, Номер 23(10), С. 1334 - 1342

Опубликована: Июль 27, 2021

Язык: Английский

---

Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium

Journal of Clinical Oncology, Год журнала: 2022, Номер 40(31), С. 3613 - 3622

Опубликована: Июнь 14, 2022

PURPOSE Seropositivity for the HPV16-E6 oncoprotein is a promising marker early detection of oropharyngeal cancer (OPC), but absolute risk OPC after positive or negative test unknown. METHODS We constructed an prediction model that integrates (1) relative odds serostatus and cigarette smoking from human papillomavirus (HPV) Cancer Cohort Consortium (HPVC3), (2) US population factor data National Health Interview Survey, (3) sex-specific rates mortality. RESULTS The nine HPVC3 cohorts included 365 participants with up to 10 years between blood draw diagnosis 5,794 controls. estimated 10-year seropositive males at age 50 was 17.4% (95% CI, 12.4 28.6) 60 27.1% 19.2 45.4). Corresponding 5-year estimates were 7.3% 14.4%, respectively. For females, 3.6% 2.5 5.9) 5.5% 3.8 9.2) 1.5% 2.7%, Over 30 years, result 49.9% 13.3% females would develop OPC. By contrast, risks among seronegative people very low, ranging 0.01% 0.25% depending on age, sex, status. CONCLUSION estimate substantial proportion individuals will OPC, 17%-27% 4%-6% 50-60 in United States. This high level may warrant periodic, minimally invasive surveillance serology test, particularly high-incidence regions. However, appropriate clinical protocol remains be established.

Язык: Английский

---

Long-term Persistence of Oral HPV Over 7 Years of Follow-up

JNCI Cancer Spectrum, Год журнала: 2020, Номер 4(5)

Опубликована: Июнь 3, 2020

Human papillomavirus-related oropharyngeal cancer (HPV-OPC) incidence is increasing, but the natural history of precursor-oral HPV-has not been well described.This observational cohort study people living with HIV and at-risk uninfected evaluated participants semiannually using 30-second oral rinse gargle specimens over 7 years. Initially, 447 were followed for 4 years as part Persistent Oral Papillomavirus Study, a subset 128 who showed persistent infections at last Study visit had an additional visit, Men Women Understanding Throat HPV on average 2.5 later. Extracted DNA from was amplified polymerase chain reaction type specification 13 oncogenic types. Risk factors clearance Cox models.The majority cleared quickly, median time to 1.4 (interquartile range = 0.5-3.9 years). After follow-up, 97% incident 71% prevalent cleared. Lower HPV-16 viral load statistically significantly associated (per 10-fold decrease in copy number: adjusted hazard ratio [aHR] 2.51, 95% confidence interval [CI] 1.20 5.26; P .01). Adjusted analyses that lower among than incident-detected (aHR 0.44, CI 0.35 0.55), men women 0.74, 0.60 0.91), older per 10 increasing age 0.81, 0.74 0.89), 0.76, 0.95). One participant consistently detected visits 4.5 subsequently diagnosed HPV-OPC.This prospective infection longest largest quantification date.

Язык: Английский

---

The Promise of Circulating Tumor DNA in Head and Neck Cancer

Cancers, Год журнала: 2022, Номер 14(12), С. 2968 - 2968

Опубликована: Июнь 16, 2022

As the seventh most common cancer globally, head and neck cancers (HNC) exert considerable disease burden, with an estimated 277,597 deaths worldwide in 2020 alone. Traditional risk factors for HNC include tobacco, alcohol, betel nut; more recently, human papillomavirus has emerged as a distinct driver of disease. Currently, limitations screening surveillance methods often lead to identifying advanced stages, associated poor outcomes. Liquid biopsies, particular circulating tumor DNA (ctDNA), offer potential enhancing screening, early diagnosis, patients, improvements patient In this review, we examine current methodologies detecting ctDNA highlight research illustrating viral non-viral biomarker utilities treatment response, prognosis. We also summarize challenges future directions testing patients.

Язык: Английский

---

Human papillomavirus (HPV) DNA methylation changes in HPV-associated head and neck cancer

Carcinogenesis, Год журнала: 2024, Номер 45(3), С. 140 - 148

Опубликована: Янв. 25, 2024

Abstract Despite the rising incidence, currently, there are no early detection methods for HPV-driven HNC (HPV-HNC). Cervical cancer studies suggest that HPV DNA methylation changes can be used as a biomarker to discriminate patients from HPV-infected individuals. As such, this study was designed establish protocol evaluate in late genes and long control region (LCR) saliva samples of HPV-HNC HPV-positive controls. Higher levels were detected (L1 L2) both tumour compared with Moreover, patterns between tumours corresponding observed have strong correlation (Passing-Bablok regression analysis; τ = 0.7483, P < 0.0001). Considering differences controls genes, considering primer amplification efficiencies, 13 CpG sites located at L1 L2 selected further evaluation. A total 18 10 assessed sites. From evaluated statistically significant identified L2—CpG 6 (P 0.0004), L1—CpG 3 0.0144), 2 0.0395) 19 0.0455). Our pilot data indicate higher indicative risk, it is potential supplementary salivary detection-based screening.

Язык: Английский

---

A Literature Review of the Potential Diagnostic Biomarkers of Head and Neck Neoplasms

Frontiers in Oncology, Год журнала: 2020, Номер 10

Опубликована: Июнь 26, 2020

Head and neck neoplasms have a poor prognosis because of their late diagnosis. Finding biomarker to detect these tumors in an early phase could improve the survival rate. This literature review provides overview biomarkers, covering different -omics fields diagnose head phase. To date, not single biomarker, nor panel biomarkers for detection has been detected with clinical applicability. Limitations implementation investigated are mainly heterogeneity study groups (e.g., small population which was tested, and/or only including high-risk populations) low sensitivity specificity under study. Further research on stage, is therefore needed.

Язык: Английский

---

Characterization of human papillomavirus (HPV) 16 E6 seropositive individuals without HPV-associated malignancies after 10 years of follow-up in the UK Biobank

EBioMedicine, Год журнала: 2020, Номер 62, С. 103123 - 103123

Опубликована: Ноя. 25, 2020

Antibodies against the HPV16 oncoprotein E6 are promising biomarkers for HPV16-driven oropharyngeal cancer (HPV16-OPC) due to their high sensitivity and specificity, prospective manifestation. In previous studies, 0•7% of controls without HPV-associated malignancies were seropositive which only a minority is expected develop cancer. We aimed characterise antibodies in individuals malignancies.

Язык: Английский

---